Opioid-Sparing Hopes, Efficacy Worries Drive Inconclusive Advisory Cmte. On Durect's Posimir

 
• By Derrick Gingery

US FDA's advisors produce tie vote on bupivacaine extended-release solution for post-surgical analgesia; proponents valued its potential to to cut opioid use, while opponents questioned its efficacy.

FDA Advisory Committee Feature image
The Anesthetic and Analgesic Drug Products Advisory Committee voted 6-6 on whether to recommend approval of Durect's post-surgical pain relief product Posimir.

More from US FDA Performance Tracker

More from Regulatory Trackers